Economic impact of tibolone compared with continuous-combined hormone replacement therapy: In the management of postmenopausal women with climacteric symptoms in the UK

PharmacoEconomics

Volumn 18, Issue 5, 2000, Pages 477-486

  Plumb, J M ^a   Guest, J F ^a  

^a CATALYST Health Economics Consultants   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL PLUS NORETHISTERONE ACETATE; KLIOFEM; TIBOLONE;

ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DRUG CHOICE; DRUG COST; ECONOMIC ASPECT; FEMALE; HORMONE SUBSTITUTION; HUMAN; MASTALGIA; MENOPAUSAL SYNDROME; MODEL; NATIONAL HEALTH SERVICE; PRESCRIPTION; PRIORITY JOURNAL; PROBABILITY; SYMPTOM; UNITED KINGDOM; VAGINA BLEEDING; WEIGHT GAIN;

EID: 0033769420     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200018050-00007     Document Type: Article

References (25)

1. Educating patients about the benefits and drawbacks of hormone replacement therapy
2. Hormone replacement therapy: Assessment of present use. Costs, and trends
3. Evaluation of a continuous combined low dose regimen of estrogen-progestin for treatment of the menopausal patient
4. The impact of different HRT regimens on compliance
5. Endocrinological studies with (7α, 17α)-17-OH-7-methyl-19-norpregn-5(10)-en-20-yn-3-one
6. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms
7. Markov models in medical decision making
8. HRT: An analysis of benefits, risks and costs
9. Cost-effectiveness of hormone replacement therapy after the menopause
10. A cost-effectiveness analysis of hormone replacement therapy in the menopause
11. The long term effectiveness of preventive strategies of osteoporosis in postmenopausal women: A modelling approach
12. Estimating the cost per avoided hip fracture by osteoporosis treatment in Italy
13. Diagnosis and management of osteoporosis in postmenopausal women: Clinical guidelines
14. Willingness to pay for hormone replacement therapy
15. Women's concerns with hormone replacement therapy - Compliance issues
16. Compliance considerations with estrogen replacement: Withdrawal bleeding and other factors
17. Hormone replacement therapy: Aspects of bleeding problems and compliance
18. The incidence of vaginal bleeding with tibolone treatment
19. Continuous combined estrogen/progestogen hormone replacement therapy
20. Effect of tibolone on post-menopausal bone loss
21. Tibolone increases bone mass in women with previous fractures in a placebo controlled bicentre study
22. Tibolone: Prevention of bone loss in late menopausal women
23. Hormone replacement therapy: Compliance and cost after screening for osteoporosis